title: Efficacy of tadalafil in chronic hypobaric hypoxia-induced pulmonary hypertension: possible mechanisms.
abstract: The present study was carried out to investigate the effects of long-acting phosphodiesterase five inhibitor, tadalafil, on pulmonary hypertension induced by chronic hypobaric hypoxia in rats. Adult Albino Wistar rats were exposed to 2 weeks of hypobaric hypoxia for 8 h daily and treated with tadalafil or tempol, a standard antioxidant agent. Right ventricular systolic pressure (RVSP) was taken as an index for pulmonary arterial pressure; malondialdehyde, reduced glutathione and superoxide dismutase were chosen as the markers of oxidative stress; serum tumour necrosis factor alpha (TNF-α) levels and inflammatory changes in lungs were assessed for inflammation. Chronic hypobaric hypoxia was found to induce pulmonary hypertension, as it significantly (P < 0.001) increased RVSP. Chronic hypobaric hypoxia also leads to an increase in oxidative stress as was evidenced by an increase in malondialdehyde levels (P < 0.001) and a significant decrease in (P < 0.001) reduced glutathione levels and superoxide dismutase activity. Chronic hypobaric hypoxia-induced inflammation was revealed by lung histology and increase in serum TNF-α levels. Tadalafil significantly prevented (P < 0.001) rise in hypobaric hypoxia-induced rise in RVSP. Tadalafil partially while tempol completely reversed hypobaric hypoxia-induced oxidative stress. Lung inflammation and serum TNF-α levels were significantly attenuated by both tadalafil and tempol. However, effect of tadalafil on inflammation was more marked than that of tempol. These data indicate that tadalafil possess antioxidant as well as antinflammatory action in addition to its vasodilatory property. All these three actions combined may have positive impact of tadalafil in the treatment of hypobaric hypoxia-induced pulmonary hypertension.
authors.affiliation: Department of Pharmacology, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi 110007, India. masratrashid1@gmail.com
authors.forename: Masrat
authors.initials: M
authors.lastname: Rashid
authors.forename: Mohammad
authors.initials: M
authors.lastname: Fahim
authors.forename: Anita
authors.initials: A
authors.lastname: Kotwani
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology; D002243:Carbolines / Q000494:pharmacology*; D003497:Cyclic N-Oxides / Q000494:pharmacology*; D004195:Disease Models, Animal; D005978:Glutathione / Q000378:metabolism; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology; D000860:Hypoxia / Q000150:complications; D007249:Inflammation / Q000188:drug therapy / Q000473:pathology; D008168:Lung / Q000187:drug effects / Q000473:pathology; D008315:Malondialdehyde / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D058986:Phosphodiesterase 5 Inhibitors / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013113:Spin Labels; D013482:Superoxide Dismutase / Q000378:metabolism; D000068581:Tadalafil; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000187:drug effects; D017725:Ventricular Pressure / Q000187:drug effects
chemical_list: D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D002243:Carbolines; D003497:Cyclic N-Oxides; D058986:Phosphodiesterase 5 Inhibitors; D013113:Spin Labels; D014409:Tumor Necrosis Factor-alpha; D008315:Malondialdehyde; D000068581:Tadalafil; D013482:Superoxide Dismutase; D005978:Glutathione; C001803:tempol